financial are starting everyone. want we morning, are to I to and Good the performance, we my believe of fundamentals on well-positioned. Al. our business comments highlight the Prior that strong Thanks,
living diseases. products with Our are patients therapies important for serious
to effectively strong us through operating enabling these We operate process, have challenging times.
to also We our well ourselves in execute commercially. ability pride
In impact are times an addition, we have These capitalized that are however unprecedented business. will well on our financially.
start COVID-XX accelerated first attributed performance, our outlook. X% to approximately we that year-over-year highlighting financial benefited up $XXX you in review for It's due on revenues. sales our now primarily Total the will to to to and with I quarter note our wrap performance important Europe. factors various I'll approximately to of the commentary our then give $X.X believe QX sense grew from revenues a billion. with million pandemic,
As in benefit million approximately a reminder, of to to QX XXXX a the sale $XXX inventory included of revenues other hemophilia due Bioverativ.
Overall, we first the prior executed OCREVUS approximately in million, of well including versus $X.X year, delivering revenues growing quarter approximately in MS X% of our billion of royalties this business, $XXX year.
year. Global royalties. US without XXXX. approximately MS US in of decrease a inventory from QX a $XXX by the increased approximately X% $XXX to channel increased year excluding versus compared MS impacted in were XXXX QX million revenues QX million decrease million $XX revenues XXXX in revenues or prior OCREVUS the OCREVUS prior versus X% of MS
in We million sales inventory $XX of change. number to shipping half impacted the the of estimate quarterly greater a additional quarter. had which due that we Roughly in days
COVID-XX In TECFIDERA. $XX benefited from believe primarily million sales addition, a we impact due net we to impacting
million primarily and MS split our $XX million, revenues price volumes, XX% Outside or higher the impact interferon. and between an on TECFIDERA impact estimated minimal of US, beneficial COVID-XX grew with $XX
revenue and quarter in prior XX% TECFIDERA first the US versus outside increased VUMERITY growth by Global and year, the driven both US. including revenues, Fumarate the
in compared or XXXX. a QX in quarter inventory US, approximately were days channel XXXX a versus without performance Fumarate million due approximately TECFIDERA with saw demand Fumarate US at of the year. we of $XX impacts. impact decrease stable the favorable for which to million grew is shipping extra X% prior revenues prior year, in Versus decrease impacted In to and COVID-XX of by first we revenue the the believe $XXX roughly primarily million those $XX underlying
QX, we US And the in million had progress XXXX. sales VUMERITY load making reimbursement. quarter $X in securing access of channel initial good of in an were first and the After
total strong with the prescriptions see light US we prior our for of fumarates stability execution increased quarter, pleased to in continued the were the share Within versus competition. of in
important order majority as to the of we due TECFIDERA via It's a vast mail US a significant that not to delivered note and the to and do impact COVID-XX. are prescriptions TECFIDERA expect in VUMERITY result
TECFIDERA to estimated XX% of revenues performed growing US, including to or inventory the with million $XX an Outside XXXX again due well approximate million, $XX very COVID-XX. benefit dynamics QX related
XX% patient patients the of TECFIDERA we Asia-Pacific XX% positive in approximately Latin year, Importantly, prior American, large X% approximately number global In growth and pleased European year-over-year. outside patient approximately patient see driven TECFIDERA combined. versus growth in to of by US grew for the were growth by markets total, the strong
shift QX the therapies. global QX to XXXX PLEGRIDY prior decreased million interferon US, efficacy revenues, platforms versus or the year. or revenues higher the to X% including both decreased In from AVONEX oral interferon and XX% injectable versus continued due $XX
a Within by the high compared US approximately inventory and AVONEX impacted $XX by [ph] $XX therapies days. continued by shipping and transition efficacy QX approximately partially to PLEGRIDY in and oral of to of decreasing million extra impacted the XXXX, the million decrease were channel
of TECFIDERA order. stable COVID-XX. Similar to an to majority in with of are benefit Outside were the interferon increased prescriptions channel the mail approximate due interferon the US revenues US, $XX delivered year to prior million related estimated the inventory versus via vast
This seeing this potential dynamic we is carefully may Given present safety products, an time erosion our their watch for properties, in an a franchise opportunity increased and going interferon interest that antiviral forward. profile we'll in progresses. which are as less
increased the TYSABRI the quarter XX% versus TYSABRI prior US the increased $XX worldwide million. versus or XX% In revenues prior million - versus revenues year XXXX. or of the first $XX
of channel in XX. of in XX US QX compared approximately revenues million approximately by to inventory were decrease increase million impacted $XX a $X TYSABRI an
quarter. adjusted total as and to Within roughly volumes increased prescriptions, as share see new pleased well of share the of US, we stable the for versus prior an prescriptions were TYSABRI
COVID-XX. approximately related increased benefit year, $X with US, TYSABRI revenues million inventory XX% the estimated prior channel increased to million to of $XX an the or versus due Outside
in related TYSABRI to QX TYSABRI adjustment X% are approximate continued due see of versus by Italy we Outside periods. pricing the prior benefited $XX to for the pleased prior revenues to US, million growth year. XXXX patient
that Given on we from COVID-XX impact sales. the office administered expect hospital is do TYSABRI physician's or TYSABRI in setting, an
within this As US working we attempt risk, to we where enable the infusions mitigate appropriate. to are home TYSABRI
with Overall, quarter. our of the pleased continued and business execution our in we performance MS franchise the were of the first strong MS
While there MS resilience is of uncertainty in particularly some encouraged and our the TYSABRI, also COVID-XX, there given opportunities by remain trajectory we are for our market leading franchise.
now excuse $XXX move In SPINRAZA revenues on first me for decreased and X% quarter year Let to prior to - QX X% increased me. the increased versus SPINRAZA X% Global revenues QX the XXXX. million. versus to XXXX US,
the on of patients by of as the by end of primarily SPINRAZA X% to adults. We believe revenues approximately compared XXXX, increased of due number US in COVID-XX. million growth driven the The quarter $X fourth to number therapy the in US benefited
a in be that seeing starts, decrease addition, in both among suggest adults, decrease well new patient as indicators particularly may COVID-XX. we compliance, a as In leading to related
make COVID-XX. aware prioritization while are and they some We difficult hospitals as decisions, physicians delaying dosesm SPINRAZA confronting are that
ensure Although we online. and I've come this more patients critical continue to back treatment receive centers work seen to
benefit increased With major versus penetration million QX primarily XX% Outside by geographies. XXXX due approximately inventory XX% to COVID-XX. across estimated an the channel increased XXXX, US, and $X all to versus driven SPINRAZA revenues QX of related increased
expect continue. moderate for to due on a seen demand impact we we SPINRAZA which the US, have may Outside COVID-XX, also
year in from of a negatively $XX impacting reminder, positive pricing France, As last comparison. benefited quarter first adjustment year-over-year million the the a of
In an Broad this SPINRAZA again total of across contributing, approximate we outside successful of very versus increased patients number regions countries continue growth commercial increased all occurred US, as prior major the XX% quarter. launch. with the the product number
pleased we SPINRAZA’s were the in performance with Overall, quarter. first
untreated we are given established of there growth, its still some pandemic, emerging the we trajectory is opportunities there continued COVID-XX including patients, believe given and many While significant for recognize markets. in in uncertainty number
this our XX% move our patients the prior Europe. estimate biosimilars approximately $XXX versus We business, or XXX,XXX in are $XX million Let to that which me in now year biosimilars there growing million. generated quarter, using now on
major as the benefiting FLIXABI approximately our BENEPALI biosimilar biosimilars versus $XX prior remains year, million five due Enbrel performed IMRALDI well prescribed well with the by US one the the potentially within EU and has geographies versus grew with Despite our to both COVID-XX to this Europe, fourth and across and opportunity grow in markets. other number additional volumes quarter, continue again the XX% XX% assets. business business grew the quarter. to volume as
anti-CDXX X% Total increased biosimilar. QX revenues with offsetting OCREVUS introduction year recent increased in revenues to of due from royalties the prior decreased RITUXAN versus
quarter other versus year, XXXX. prior of revenues Total $XXX of period the approximately sale first first XX% to in in million the decreased r primarily the due quarter to inventory of the hemophilia Bioverativ
revenue and relatively the the Let to due lower XX%, manufacturing now XXXX was gross to me prior turn stable versus QX margins. gross the XX% in contract prior margin was an quarter. improvement year, versus
expense revenue. and of QX both GAAP were XX% R&D non-GAAP
expense Skyhawk, net $XX aducanumab. studies the our XXXX III and reminder, the approximately agreement included As approximate costs in for a Phase R&D in with of related million quarter to million of first $XX closeout
Note, lower was to are and milestones predict. to for license million non-GAAP we fee expect part in Sangamo. difficult to which the related of of in with quarter expense XXXX record timing to in our R&D XXXX of collaboration QX the R&D a expense the GAAP second $XXX
XX% both of year, for as our were We increase commercial SG&A aducanumab. we still non-GAAP and expect preparations throughout revenue. GAAP the to QX ramp up SG&A
million. primarily on fair was in our decrease by equity $XX which million other other unrealized the $XX Ionis. million, included expense GAAP in investments, investment losses expense was in value of QX driven $XXX QX non-GAAP
tax XXXX gains. our higher our unrealized year, time the first In quarter were manufacturing of planned tax In non-GAAP as related and approximate GAAP charge QX this Denmark Hillerød. to well one XX%. included of as rates rate GAAP divestiture a operations, the both our FX
first first repurchased the in We at shares authorized program approximately quarter of share now March has approximately a and quarter under The the program repurchase of XXXX in million the authorized been an $XXX as of the for share in end average completed December. remaining repurchase value billion was price billion. X.X of $X.X $X.X total approximately
the prior our of and That increase booked a GAAP prior year. versus now earnings the the XX% In year brings per to EPS diluted $X.XX of us non-GAAP share, of per an we XX% increase $X.XX, share. versus first quarter earnings
We generated million cash We $X.X and from flows in QX. billion in in ended securities net $X.X debt. approximately cash, the billion operations with approximately quarter $X marketable in
of that these think we we balance the unprecedented there's significant the and As uncertainty. about year, are acknowledge times
do know. benefit me quarter outline saw We from relative that occurred performed some the Let first we what now to accelerated again and in COVID-XX. sales operationally well
some the expect revenues between quarters. We volatility in
TYSABRI some We facility as for dosing. and seen have to we have some start capacity, in physician administration due to seen and SPINRAZA delays materialize, disruption particularly
We therapies essential maintain patients to we actively dosing are working patients believe their and help schedules. for are our
are and including systems, of environment payer from the mindful impact impact risks We macro a the care potential potential mix. on the on health also economic the
At these past, commercial the may we time, focused same part execution, we the help in demonstrated remain mitigate in believe as on risks. strong which
pressures in potential benefit and areas We therapies. potentially interferon our a interest decrease in from across business several also competitive may renewed
then. July know guidance policy update we and to and once should hopefully a As more reminder, we our a in by have a year
Michel now me for to comments. over turn Let closing back the his call
